Type 2 diabetes is common; it affects one in ten adults internationally and one in five adults aged 65 years or older. It is ...

These trials have shown efficacy for GLP-1 receptor agonism in patients with heart failure with preserved ejection fraction and obesity. However, we await further trials to expand the evidence.

Dopamine’s involvement in Alzheimer’s treatment stems from its ability to stimulate the production of neprilysin, an enzyme crucial for breaking down beta-amyloid. Neprilysin acts as a natural ...

Researchers have discovered that sacubitril/valsartan, the angiotensin receptor-neprilysin inhibitor (ARNI), is equivalent to the conventional angiotensin-converting enzyme (ACE) inhibitor enalapril ...

Current treatments for HFpEF for women include angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, sodium-glucose cotransporter 2 (SGLT2) inhibitors and GLP-1 ...

The probability of event-free survival in patients receiving valsartan 160 mg b.i.d. vs. placebo in addition to optimal medical therapy in patients with systolic heart failure (Kaplan-Meier ...

And results of the SUMMIT trial—reported last month at the American Heart Association (AHA) 2024 Scientific Sessions—showed that tirzepatide (Zepbound; Eli Lilly), a dual glucose-dependent ...

angiotensin-converting-enzyme inhibitors/angiotensin-receptor blocker/angiotensin receptor neprilysin inhibitor and/or low dose colchicine. Thus, the challenge for clinicians will be to effectively ...

Epidermal growth factor receptor (EGFR) is expressed in 50% of NSCLCs, and its expression is correlated with poor prognosis. These two factors make EGFR and its family members prime candidates for ...

ACEis, ARBs and CCB-DHPs were classified as afterload-reducing drugs. No patient was on angiotensin receptor neprilysin inhibitor (ARNI) at initial presentation. Therefore, use of ARNI has not been ...